Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioGeneriX AG
Mannheim, Baden-Württemberg, Germanybiogenerix.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
BioGeneriX AG, founded in Germany in June 2000, specializes in the preclinical and clinical development of biosimilars. The company has sponsored or collaborated on at least seventeen clinical trials, including multiple completed Phase III studies for biosimilar products such as XM22 (pegfilgrastim) and XM17 (recombinant FSH). It operates as a division of Teva Pharmaceuticals and focuses on developing biopharmaceutical drugs with known modes of action targeting established drug markets. Clinical results indicate successful completion of pivotal studies supporting regulatory filings for their lead programs.
- Therapeutic areas
- OncologyWomen's Health
- Modalities
- Biosimilars (recombinant proteins, therapeutic antibodies)
- Industry
- Biotech
02
Partnerships
Asset purchase from Neose Technologies Inc.Collaborations with multinational clinical sites for trials.
Beyond the preview
Go deeper on BioGeneriX AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioGeneriX AG.